Voices
Alexandre Reuben Introduces the ATTACH Platform for Antigen-Specific T Cell Isolation
Alexandre Reuben/mdanderson.org

Alexandre Reuben Introduces the ATTACH Platform for Antigen-Specific T Cell Isolation

Alexandre Reuben, Assistant Professor at MD Anderson, Director, Immunology Program at GSBS, Founder of Tenaci-T Therapeutics and Founder of ATTACHbio, shared a post on LinkedIn:

“Unbiased avidity-based isolation of antigen-specific T cells.

I could not be more excited to share our lab’s most recent publication describing the ATTACH platform (Assessment of T cells Tethered to Antigen Class I/II Histocompatibility) and its potential for the isolation of antigen-specific T cells in lung cancer which is now published in the Journal for ImmunoTherapy of Cancer. This started back in 2019. Here are the highlights:

  1. Microfluidic platform for isolation of antigen-specific T cells based on their ability to engage their targets through TCR-MHC/peptide interactions leveraging fluidic shear stress (no functional or phenotypic readout required);
  2. No requirement for prior antigen identification, peptide synthesis, tetramer synthesis, functional analysis, and phenotyping. However, target cells are required;
  3. Rapid enrichment for antigen-specific T cells using consistent, versatile parameters;
  4. Enrichment achieved for antigen-specific T cells in mouse and human systems, different MHC/HLAs (H2-Kb, HLA-A02:01, HLA-A03:01, etc), different classes of tumor antigens (foreign, tumor-associated antigen, point mutation, etc);
  5. Effective depletion of bystander T cells recognizing viral antigens;
  6. Recovery of antigen-specific T cells at a sensitivity of 1/1000 (0.1%);
  7. Functional T cells recovered for downstream applications;
  8. Platform could be used in many different disease settings beyond cancer and cell therapy.

Outstanding work by lead author Amanda Montoya and co-authors Meredith Frank, MS, Peixin Jiang, Hui Nie, Minying Zhang, Emily Bontekoe, Jared Slone, Ludovica La Posta, Sofia Rosy Caterina Sorice, Tina Cascone, Maura Gillison, Don Gibbons, Jianjun Zhang, Eleonora Dondossola, Lydia E. Kavraki, Pamela Wenzel, and John Heymach.

Thank you to our incredible funders who supported this work: Rexanna’s Foundation, The Lance Bertrand Research Grant, MD Anderson’s Lung Cancer Moon Shot, National Cancer Institute (NCI), US Department of Defense CDMRP Lung Cancer Research Program, Cancer Prevention and Research Institute of Texas.

We look forward to continuing to develop the ATTACH platform to refine cell therapies across the spectrum – this technology is now being advanced by Attach Bio (www.attachbio.com)!

Study can be found here.”

Other articles about Lung Cancer on OncoDaily.

Alexandre Reuben Amanda Montoya Antigen-Specific T Cells Assessment of T Cells Tethered to Antigen Class I/II Histocompatibility Attach Bio ATTACH Platform cancer cancer immunology Cancer Prevention and Research Institute of Texas CAR T-cell therapy CDMRP Lung Cancer Research Program Cell Therapy CPRIT Don Gibbons Eleonora Dondossola Emily Bontekoe HLA Hui Nie immunotherapy Jared Slone Jianjun Zhang John Heymach Journal for ImmunoTherapy of Cancer Ludovica La Posta Lung cancer Lung Cancer Moon Shot Lydia E. Kavraki Maura Gillison MD Anderson Cancer Center Meredith Frank MHC Microfluidics Minying Zhang National Cancer Institute NCI OncoDaily Oncology Pamela Wenzel Peixin Jiang Precision Oncology Rexanna's Foundation Sofia Rosy Caterina Sorice T cells TCR The Lance Bertrand Research Grant Tina Cascone translational research Tumor antigens tumor microenvironment US Department of Defense